In recent years, glucagon-like peptide-1 receptor agonist (GLP-1RA) and dual glucose-dependent insulinotropic peptide (GIP) and GLP-1 RA have been used as treatments for obesity, but there have been reports raising concerns about muscle weakness due to weight loss [32]. The gene discussed is GIP; the disease is Obesity.